Aprotinin Articles
Nordic Group gets ex-US right to Trasylol from Bayer
15 July 2012
EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri
20 February 2012
Bayer pulls remaining stocks of Trasylol
19 May 2008
US law suits filed over Trasylol kidney AEs
25 February 2008
Study finds Tasylol safe in certain surgeries
18 February 2008
EMEA suspends use of aprotinin drugs
3 December 2007
Bayer temporarily stops Trasylol marketing
21 November 2007
New Trasylol warnings after BART study deaths
5 November 2007
Stock Commentary - Europe - week to Sept 10, 2007
17 September 2007
CRDAC recommends FDA OK for Trasylol
17 September 2007
Bayer did not withhold Trasylol safety data
3 September 2007
Bayer's Trasylol linked to CABG mortality risk
12 February 2007
Stock Commentary - Europe - week to Jan 29, 2007
5 February 2007
Bayer stops non-CABG Trasylol studies
5 February 2007
Bayer announces Trasylol label revisions
22 December 2006
Bayer appoints independent Trasylol investigator
23 October 2006
FDA public advisory on Bayer
9 October 2006
Trasylol endorsed by FDA in CABG surgery
2 October 2006
Bayer's income reaches 1.59B in 2005, up 133%
13 March 2006
Stock Commentary - Europe - week to Feb 13, 2006
20 February 2006
FDA issues "advisory" on Bayer's Trasylol
20 February 2006
Stock Commentary - Europe - week to feb 6
13 February 2006
Stock Commentary - Europe - week to Jan 30
6 February 2006
NEJM study finds health risks associated with Bayer's Trasylol
30 January 2006
Bayer initiates Ph III Trasylol study
19 December 2005
Bayer Corp starts Ph III evaluation of Trasyol
18 April 2005
Bayer and Schering-Plough form strategic pharmaceuticals alliance
20 September 2004
Bayer Details Near-Term Product Expectations
1 April 1996
Bayer's First Pipeline Presentation: Part 1
19 June 1995
MILES FILES SUPPLEMENTAL NDA
18 April 1994
FDA YEAR-END APPROVALS FOR 1993
10 January 1994
NOVO NORDISK EXPANDING ITS FOCUS
26 April 1993
PROJECT REVIEW FROM NOVO NORDISK
27 April 1992
Showing 1-37 of 37 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
